US 11,998,593 B2
Combination vaccine devices and methods of killing cancer cells
Omar Abdel-Rahman Ali, Oakland, CA (US); David J. Mooney, Sudbury, MA (US); and Glenn Dranoff, Sudbury, MA (US)
Assigned to President and Fellows of Harvard College, Cambridge, MA (US); and Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Filed by President and Fellows of Harvard College, Cambridge, MA (US); and Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Filed on May 18, 2020, as Appl. No. 16/877,274.
Application 16/877,274 is a continuation of application No. 15/303,985, granted, now 10,682,400, previously published as PCT/US2015/028468, filed on Apr. 30, 2015.
Claims priority of provisional application 61/986,600, filed on Apr. 30, 2014.
Prior Publication US 2020/0276290 A1, Sep. 3, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 39/02 (2006.01); A61K 39/12 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61K 47/34 (2017.01); A61K 47/36 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 7/00 (2006.01)
CPC A61K 39/0011 (2013.01) [A61K 39/001102 (2018.08); A61K 39/001156 (2018.08); A61K 39/001157 (2018.08); A61K 39/00117 (2018.08); A61K 39/001171 (2018.08); A61K 39/00118 (2018.08); A61K 39/001182 (2018.08); A61K 39/001186 (2018.08); A61K 39/001191 (2018.08); A61K 39/001192 (2018.08); A61K 39/02 (2013.01); A61K 39/12 (2013.01); A61K 39/39 (2013.01); A61K 39/3955 (2013.01); A61K 47/34 (2013.01); A61K 47/36 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/30 (2013.01); C07K 16/3053 (2013.01); C12N 7/00 (2013.01); A61K 2039/507 (2013.01); A61K 2039/5152 (2013.01); A61K 2039/54 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/55522 (2013.01); A61K 2039/55561 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01)] 21 Claims
 
1. A method of treating a poorly immunogenic cancer in a subject in need thereof, wherein the poorly immunogenic cancer is resistant to cytotoxic T-lymphocyte (CTL)-mediated lysis or natural killer (NK) cell mediated killing, the method comprising administering to the subject:
a) an inhibitor of an immune checkpoint protein; and
b) a device comprising
(i) a macroporous scaffold composition comprising open, interconnected pores,
(ii) a cell recruitment composition that recruits an immune cell, wherein the cell recruitment composition is selected from the group consisting of a cytokine, a chemokine, a growth factor, and a combination thereof; and
(iii) an antigen derived from the cancer,
wherein the inhibitor is administered concurrent and subsequent to the administration of the device, wherein the subsequent administration is in the absence of the device, and wherein the method enhances the CD8 T cell: Treg cell ratio in the cancer, thereby treating the cancer.